7.2 Hypoxic-Ischemic Encephalopathy (HIE) & Therapeutic Hypothermia

Hypoxic-Ischemic Encephalopathy (HIE) & Therapeutic Hypothermia

Pathophysiology of Perinatal Asphyxia and Encephalopathy

Hypoxic-Ischemic Encephalopathy (HIE) is a significant cause of neonatal mortality and long-term neurodevelopmental disability. It results from a perinatal hypoxic-ischemic insult that impairs cerebral blood flow and oxygen delivery. The neuronal injury occurs in two distinct phases: primary and secondary energy failure.

1. Primary Energy Failure: Immediate consequence of the hypoxic-ischemic insult. The deprivation of oxygen and glucose forces brain tissue into anaerobic metabolism, which is highly inefficient and leads to rapid depletion of adenosine triphosphate (ATP). The loss of ATP causes the failure of energy-dependent sodium-potassium (Na+/K+) ATPase pumps on cell membranes. This failure leads to intracellular accumulation of sodium and water, resulting in cytotoxic edema and cellular depolarization. Membrane depolarization triggers a massive influx of calcium into neurons and the excessive, uncontrolled release of excitatory neurotransmitters (primarily glutamate) into the synaptic cleft. Glutamate over-activates N-methyl-D-aspartate (NMDA) and AMPA receptors, allowing further toxic calcium entry. Elevated intracellular calcium activates destructive intracellular enzymes (proteases, lipases, endonucleases), culminating in rapid necrotic cell death.
2. Secondary Energy Failure: Occurs 6 to 24 hours after the initial insult, following a brief period of apparent cellular recovery (the latent phase). During this phase, which can last for days, reoxygenation and reperfusion paradoxically trigger a secondary injury cascade. This is characterized by mitochondrial dysfunction, the generation of reactive oxygen species (free radicals), nitric oxide toxicity, microglial activation, and a severe neuroinflammatory response. These processes lead to apoptotic cell death (programmed cell death) rather than necrosis. The latent phase between primary and secondary energy failure represents the critical therapeutic window (under 6 hours from birth) during which hypothermia must be initiated to disrupt this secondary cascade.

Sarnat Staging for HIE Severity

The Sarnat classification system is used to evaluate the clinical severity of HIE during the first few days of life, which correlates directly with long-term prognosis.

Therapeutic Hypothermia Criteria and Protocols

Therapeutic hypothermia is the only proven neuroprotective intervention that reduces mortality and improves neurodevelopmental outcomes in infants with moderate-to-severe HIE.

Inclusion Criteria

Infants must meet all of the following criteria to qualify for cooling:

1. Gestational age >= 35 weeks and birth weight >= 1800 g.
2. Evidence of acute perinatal depression (at least one of the following):
   • Apgar score <= 5 at 10 minutes.
   • Ongoing resuscitation or positive pressure ventilation/intubation at 10 minutes.
   • Umbilical cord gas or first postnatal blood gas (within 1 hour of birth) pH < 7.00.
   • Umbilical cord gas or first postnatal blood gas (within 1 hour of birth) base deficit >= 16 mmol/L.
3. Evidence of moderate-to-severe encephalopathy on clinical exam (e.g., altered consciousness, hypotonia, abnormal reflexes, seizures) and/or confirmed by amplitude-integrated EEG (aEEG) showing moderate or severe background abnormalities.

Whole-Body vs. Selective Head Cooling

• Whole-Body Cooling: The infant lies on a cooling blanket that is servo-controlled to maintain a core body temperature of 33.5°C (acceptable range 33.0°C to 34.0°C). It is widely preferred due to its ease of use, ability to maintain continuous EEG electrode placement without interference, and uniform cooling of deep brain structures.
• Selective Head Cooling: A special cap circulating cold water is placed on the infant's head to lower brain temperature, while a radiant warmer maintains systemic core temperature slightly higher (body temperature around 34.5°C). Clinical trials have demonstrated equivalent neuroprotective efficacy between the two methods.

Protocol Details

• Timing: Must be initiated within 6 hours of birth to target the latent phase before secondary energy failure begins.
• Duration: Maintained continuously for 72 hours.
• Rewarming: After 72 hours, the infant is slowly rewarmed to normal core temperature (36.5°C to 37.0°C) at a rate of 0.5°C per hour over approximately 6 hours. Rapid rewarming must be strictly avoided.

Physiological Changes and Side Effects of Cooling

Hypothermia impacts multiple organ systems, and nursing staff must anticipate and monitor these physiological alterations:

• Cardiovascular: Sinus bradycardia is the most common physiological response, with heart rates typically dropping to 80-100 beats per minute. This is expected and does not require intervention if blood pressure, capillary refill, and peripheral perfusion remain adequate. Prolonged PR and QT intervals can occur on EKG. Systemic hypotension may occur and is treated with volume expansion or vasoactive medications (dopamine/dobutamine).
• Hematological: Thrombocytopenia and mild coagulopathy are common due to platelet sequestration in the liver and spleen, as well as impaired coagulation enzyme function at lower temperatures. Bleeding (e.g., oozing from puncture sites, pulmonary hemorrhage) should be monitored.
• Metabolic: Hypokalemia is common during the cooling phase because potassium shifts intracellularly. During rewarming, potassium shifts back out of cells; if rewarming is too rapid, rebound hyperkalemia can occur, risking cardiac arrhythmias. Glucose instability (hypoglycemia or hyperglycemia) is also common.
• Renal: Hypoxia-ischemia often causes acute kidney injury (AKI) with renal tubular dysfunction, resulting in oliguria and fluid overload.
• Respiratory: Hypothermia causes pulmonary vasoconstriction, which can exacerbate or trigger Persistent Pulmonary Hypertension of the Newborn (PPHN), leading to severe hypoxemia.
• Integumentary: Subcutaneous fat necrosis can present as firm, erythematous nodules on the back, buttocks, or limbs. This is rare but can cause hypercalcemia weeks after cooling is completed.

Nursing Management

• Temperature Monitoring: Continuous core temperature monitoring using a rectal or esophageal probe (inserted 5-10 cm) is mandatory. Secure the probe to prevent displacement. A skin probe is placed as a backup.
• Fluid Management: Restrict fluids to 50-60 mL/kg/day to minimize cerebral edema and prevent fluid overload in the setting of oliguric AKI.
• Sedation: Monitor for shivering, which increases metabolic rate, oxygen consumption, and heat production, negating the neuroprotective effects of cooling. Low-dose morphine or fentanyl is administered to control discomfort and shivering.
• Neuro-monitoring: Assess pupillary size and response, muscle tone, and activity. Continuous aEEG is used to monitor background cerebral activity and detect subclinical seizures.
• Rewarming Care: Monitor closely for hypotension, tachycardia, hypoxemia, hypoglycemia, and rebound seizures. If the infant exhibits clinical instability during rewarming, the rewarming process should be paused or slowed.

Clinical Tips & Exam Traps

• Exam Trap: Physiological bradycardia during cooling (e.g., HR 85 bpm) does not require intervention if perfusion and blood pressure are normal. Avoid atropine or pacing.
• Exam Trap: If an infant starts seizing or becomes hypotensive during rewarming, the nurse should immediately stop the rewarming process, stabilize the infant, and resume a slow rewarming rate once stabilized.